Extent of Signal Hyperintensity on Unenhanced T1-weighted Brain MR Images after More than 35 Administrations of Linear Gadolinium-based Contrast Agents

Published Online:https://doi.org/10.1148/radiol.2016152864

Increased signal intensity on unenhanced T1-weighted MR images in the dentate nucleus, globus pallidus, posterior thalamus, substantia nigra, red nucleus, cerebellar peduncles, and colliculi may relate to gadolinium-based contrast agent (GBCA) administration in patients who receive many GBCA administrations.


To explore the extent of signal hyperintensity in the brain on unenhanced T1-weighted magnetic resonance (MR) images with increasing gadolinium-based contrast agent (GBCA) doses in patients who received 35 or more linear GBCA administrations.

Materials and Methods

In this institutional review board–approved HIPAA-compliant retrospective study, picture archiving and communication systems of two tertiary referral hospitals were searched to identify patients who received 35 or more linear GBCA administrations. Unenhanced T1-weighted images of the brain in patients after six, 12, and 24 GBCA administrations and after the final GBCA administration were independently reviewed by three radiologists to identify sites where T1 signal intensity was increasing. Areas identified by all three observers as increasing in T1 signal intensity when compared with baseline images were further analyzed with a quantitative region of interest analysis measuring the rate of signal increase per injection and the total change after 24 linear GBCA administrations relative to reference tissues that did not show T1 shortening.


Qualitative analysis of 13 patients with 39–59 linear GBCA administrations showed visually detectable T1 shortening in the dentate nucleus (n = 13), globus pallidus (n = 13), substantia nigra (n = 13), posterior thalamus (n = 12), red nucleus (n = 10), colliculi (n = 10), superior cerebellar peduncle (n = 7), caudate nucleus (n = 4), whole thalamus (n = 3), and putamen (n = 2). Quantitative analysis enable confirmation of signal intensity increases on unenhanced T1-weighted images relative to reference tissues in the dentate nucleus (0.53% signal intensity increase per injection, P < .001), globus pallidus (0.23% increase, P = .009), posterior thalamus (0.26% increase, P < .001), substantia nigra (0.25% increase, P = .01), red nucleus (0.25% increase, P = .01), cerebellar peduncle (0.19% increase, P = .001), and colliculi (0.21% increase, P = .02).


Increased signal intensity on unenhanced T1-weighted images was seen in the posterior thalamus, substantia nigra, red nucleus, cerebellar peduncle, colliculi, dentate nucleus, and globus pallidus.

© RSNA, 2016

An earlier incorrect version of this article appeared online. This article was corrected on January 26, 2017.


  • 1. Kanda T, Ishii K, Kawaguchi H, Kitajima K, Takenaka D. High signal intensity in the dentate nucleus and globus pallidus on unenhanced T1-weighted MR images: relationship with increasing cumulative dose of a gadolinium-based contrast material. Radiology 2014;270(3):834–841. LinkGoogle Scholar
  • 2. Radbruch A, Weberling LD, Kieslich PJ, et al. Gadolinium retention in the dentate nucleus and globus pallidus is dependent on the class of contrast agent. Radiology 2015;275(3):783–791. LinkGoogle Scholar
  • 3. Errante Y, Cirimele V, Mallio CA, Di Lazzaro V, Zobel BB, Quattrocchi CC. Progressive increase of T1 signal intensity of the dentate nucleus on unenhanced magnetic resonance images is associated with cumulative doses of intravenously administered gadodiamide in patients with normal renal function, suggesting dechelation. Invest Radiol 2014;49(10):685–690. Crossref, MedlineGoogle Scholar
  • 4. Weberling LD, Kieslich PJ, Kickingereder P, et al. Increased signal intensity in the dentate nucleus on unenhanced T1-weighted images after gadobenate dimeglumine administration. Invest Radiol 2015;50(11):743–748. Crossref, MedlineGoogle Scholar
  • 5. Ramalho J, Castillo M, AlObaidy M, et al. High signal intensity in globus pallidus and dentate nucleus on unenhanced T1-weighted MR images: evaluation of two linear gadolinium-based contrast agents. Radiology 2015;276(3):836–844. LinkGoogle Scholar
  • 6. Quattrocchi CC, Mallio CA, Errante Y, et al. Gadodiamide and dentate nucleus T1 hyperintensity in patients with meningioma evaluated by multiple follow-up contrast-enhanced magnetic resonance examinations with no systemic interval therapy. Invest Radiol 2015;50(7):470–472. Crossref, MedlineGoogle Scholar
  • 7. McDonald RJ, McDonald JS, Kallmes DF, et al. Intracranial gadolinium deposition after contrast-enhanced MR imaging. Radiology 2015;275(3):772–782. LinkGoogle Scholar
  • 8. Kanda T, Osawa M, Oba H, et al. High signal intensity in dentate nucleus on unenhanced T1-weighted MR images: association with linear versus macrocyclic gadolinium chelate administration. Radiology 2015;275(3):803–809. LinkGoogle Scholar
  • 9. Adin ME, Kleinberg L, Vaidya D, Zan E, Mirbagheri S, Yousem DM. Hyperintense dentate nuclei on T1-weighted MRI: relation to repeat gadolinium administration. AJNR Am J Neuroradiol 2015;36(10):1859–1865. Crossref, MedlineGoogle Scholar
  • 10. Cao Y, Huang DQ, Shih G, Prince MR. Signal change in the dentate nucleus on T1-weighted MR images after multiple administrations of gadopentetate dimeglumine versus gadobutrol. AJR Am J Roentgenol 2016;206(2):414–419. Crossref, MedlineGoogle Scholar
  • 11. Kanda T, Oba H, Toyoda K, Furui S. Recent advances in understanding gadolinium retention in the brain. AJNR Am J Neuroradiol 2016;37(1):E1–E2. Crossref, MedlineGoogle Scholar
  • 12. Runge VM. Safety of the gadolinium-based contrast agents for magnetic resonance imaging, focusing in part on their accumulation in the brain and especially the dentate nucleus. Invest Radiol 2016;51(5):273–279. Crossref, MedlineGoogle Scholar
  • 13. Quattrocchi CC, Mallio CA, Errante Y, Beomonte Zobel B. High T1 signal intensity in dentate nucleus after multiple injections of linear gadolinium chelates. Radiology 2015;276(2):616–617. LinkGoogle Scholar
  • 14. Karabulut N. Gadolinium deposition in the brain: another concern regarding gadolinium-based contrast agents. Diagn Interv Radiol 2015;21(4):269–270. Crossref, MedlineGoogle Scholar
  • 15. Miller JH, Hu HH, Pokorney A, Cornejo P, Towbin R. MRI brain signal intensity changes of a child during the course of 35 gadolinium contrast examinations. Pediatrics 2015;136(6):e1637–e1640. Crossref, MedlineGoogle Scholar
  • 16. Kanda T, Fukusato T, Matsuda M, et al. Gadolinium-based contrast agent accumulates in the brain even in subjects without severe renal dysfunction: evaluation of autopsy brain specimens with inductively coupled plasma mass spectroscopy. Radiology 2015;276(1):228–232. LinkGoogle Scholar
  • 17. Aime S, Caravan P. Biodistribution of gadolinium-based contrast agents, including gadolinium deposition. J Magn Reson Imaging 2009;30(6):1259–1267. Crossref, MedlineGoogle Scholar
  • 18. Oksendal AN, Hals PA. Biodistribution and toxicity of MR imaging contrast media. J Magn Reson Imaging 1993;3(1):157–165. Crossref, MedlineGoogle Scholar
  • 19. Brasch RC, Weinmann HJ, Wesbey GE. Contrast-enhanced NMR imaging: animal studies using gadolinium-DTPA complex. AJR Am J Roentgenol 1984;142(3):625–630. Crossref, MedlineGoogle Scholar
  • 20. Stojanov DA, Aracki-Trenkic A, Vojinovic S, Benedeto-Stojanov D, Ljubisavljevic S. Increasing signal intensity within the dentate nucleus and globus pallidus on unenhanced T1W magnetic resonance images in patients with relapsing-remitting multiple sclerosis: correlation with cumulative dose of a macrocyclic gadolinium-based contrast agent, gadobutrol. Eur Radiol 2016;26(3):807–815. Crossref, MedlineGoogle Scholar
  • 21. Valdés Hernández MdelC, Maconick LC, Tan EM, Wardlaw JM. Identification of mineral deposits in the brain on radiological images: a systematic review. Eur Radiol 2012;22(11):2371–2381. Crossref, MedlineGoogle Scholar
  • 22. Shin YC, Kim E, Cheong HK, et al. High signal intensity on magnetic resonance imaging as a predictor of neurobehavioral performance of workers exposed to manganese. Neurotoxicology 2007;28(2):257–262. Crossref, MedlineGoogle Scholar
  • 23. Mirowitz SA, Westrich TJ, Hirsch JD. Hyperintense basal ganglia on T1-weighted MR images in patients receiving parenteral nutrition. Radiology 1991;181(1):117–120. LinkGoogle Scholar
  • 24. da Silva CJ, da Rocha AJ, Jeronymo S, et al. A preliminary study revealing a new association in patients undergoing maintenance hemodialysis: manganism symptoms and T1 hyperintense changes in the basal ganglia. AJNR Am J Neuroradiol 2007;28(8):1474–1479. Crossref, MedlineGoogle Scholar
  • 25. Lai PH, Chen C, Liang HLPH, Pan HB. Hyperintense basal ganglia on T1-weighted MR imaging. AJR Am J Roentgenol 1999;172(4):1109–1115. Crossref, MedlineGoogle Scholar
  • 26. Rovira A, Alonso J, Córdoba J. MR imaging findings in hepatic encephalopathy. AJNR Am J Neuroradiol 2008;29(9):1612–1621. Crossref, MedlineGoogle Scholar
  • 27. Brunberg JA, Kanal E, Hirsch W, Van Thiel DH. Chronic acquired hepatic failure: MR imaging of the brain at 1.5 T. AJNR Am J Neuroradiol 1991;12(5):909–914. MedlineGoogle Scholar
  • 28. Kim TJ, Kim IO, Kim WS, et al. MR imaging of the brain in Wilson disease of childhood: findings before and after treatment with clinical correlation. AJNR Am J Neuroradiol 2006;27(6):1373–1378. MedlineGoogle Scholar
  • 29. Nieto D, Nieto A. Neurochemical significance of the red nucleus. Bull Clin Neurosci 1986;51:89–93. MedlineGoogle Scholar
  • 30. Schwarz ST, Rittman T, Gontu V, Morgan PS, Bajaj N, Auer DP. T1-weighted MRI shows stage-dependent substantia nigra signal loss in Parkinson’s disease. Mov Disord 2011;26(9):1633–1638. Crossref, MedlineGoogle Scholar

Article History

Received December 25, 2015; revision requested February 8, 2016; revision received May 21; accepted May 27; final version accepted June 3.
Published online: Aug 11 2016
Published in print: Feb 2017